医学
腺癌
插入
肿瘤科
肺
癌症研究
内科学
外显子
肺腺癌
癌症
突变
生物
基因
遗传学
作者
Tao Luan,Xinqing Lin,Xie Xiaohong,Gang Yang,Shuaiying Wang,Jianqing Hao,C. Zhou
标识
DOI:10.1097/cad.0000000000001628
摘要
Human epidermal growth factor receptor 2 (HER2) is a transmembrane glycoprotein receptor with intracellular tyrosine kinase activity. It is generally considered as a poor prognostic marker. Targeted therapies, such as small molecule tyrosine kinase inhibitors (TKIs), showed limited efficacy in HER2-mutant advanced nonsmall cell lung cancer (NSCLC). In the 2023 National Comprehensive Cancer Network guidelines for NSCLC, antibody-drug conjugate trastuzumab emtansine is recommended for the treatment of HER2-mutant lung cancer. However, this medication is currently not approved in certain regions.So it is necessary to explore alternative treatment options for HER2-mutant NSCLC patients. In our study of a patient with HER2 exon 20 insertion lung adenocarcinoma who had previously failed multiple epidermal growth factor receptor (EGFR)-TKI treatments, we discovered that sunvozertinib could stabilize the patient’s condition, achieving a progression-free survival of 87 days. This is a novel finding that may provide new treatment options for HER2 exon 20 insertion patients who have failed TKI therapy.
科研通智能强力驱动
Strongly Powered by AbleSci AI